-
Eltanexor: From Nuclear Export to Translation
2026-08-12
Eltanexor (KPT-8602) illustrates how selective XPO1 inhibition can connect nuclear transport biology with translational strategies in AML, CLL, lymphoma, and colorectal cancer. This thought-leadership analysis interprets the mechanistic evidence, defines practical study parameters, and outlines biomarker-led paths for advancing cancer therapeutics targeting nuclear export.
-
SAR405: Decoding Vps34 Under Energy Stress
2026-08-11
SAR405 is a selective Vps34 inhibitor for dissecting autophagy inhibition, PtdIns3P production, and lysosomal responses. This article connects emerging AMPK–ULK1 biology with compartment-resolved assay design for more rigorous interpretation in cancer research.
-
Entecavir: Evidence for Chronic Hepatitis B Therapy
2026-08-11
Fabien Zoulim’s 2006 review positioned Entecavir, also known as BMS200475, as a potent nucleoside analogue that could improve chronic hepatitis B management through stronger viral suppression and a favorable early resistance profile. The article integrates biochemical, cell-culture, animal, and clinical evidence while showing why persistent cccDNA and resistance selection remain central limitations.
-
Galectin-1, FIP200, and Autophagy in NAFLD
2026-08-10
A 2026 study identifies a direct Galectin-1–FIP200 interaction as an upstream brake on hepatic autophagy, linking this mechanism to steatosis, dyslipidemia, and insulin resistance. Its combination of mouse gain-of-function models, proteomic profiling, binding analysis, and interaction-disrupting mutations provides a mechanistic framework for metabolic liver disease research.
-
HyperScript III RT SuperMix for CRC qPCR
2026-08-09
HyperScript III RT SuperMix supports rigorous two-step qRT-PCR validation of colorectal cancer biomarkers, including challenging low-input and high-GC RNA. This article translates bile acid–based transcriptomic findings into practical, contamination-aware assay decisions.
-
Diethylmaleate for GST and Redox Studies
2026-08-08
Diethylmaleate is a practical redox perturbation tool for linking intracellular glutathione depletion with ROS, apoptosis, and stress adaptation. This guide translates insecticide-resistance findings into reproducible workflows for cell, toxicology, and organismal assays while emphasizing solvent controls, timing, and mechanistic limits.
-
Cy5 maleimide (non-sulfonated) Protocol
2026-08-07
Cy5 maleimide (non-sulfonated) is a thiol-reactive labeling reagent for attaching a near-red fluorophore to accessible cysteine residues in peptides and proteins. This guide covers solvent handling, conjugation setup, optical QC, and troubleshooting; it should not be used to infer labeling performance in a specific protein or biological system without empirical validation.
-
Dual FOXO3-Mediated Metabolic Inhibition in HCC: Mechanisms
2026-08-07
This study identifies FOXO3 as a tumor suppressor in hepatocellular carcinoma (HCC) that inhibits both glycolysis and glutaminolysis by repressing YAP-driven metabolic programs. Pharmacological activation of FOXO3 leads to significant impairment of HCC cell proliferation and viability, highlighting a promising metabolic intervention strategy.
-
GSTA1 Drives Glutathione Depletion in α-Amanitin Hepatotoxic
2026-08-06
This study reveals that upregulation of GSTA1 exacerbates α-amanitin-induced liver injury not by protecting against oxidative stress, but by accelerating glutathione depletion and reactive oxygen species accumulation. The findings reposition GSTA1 as a potential therapeutic target and biomarker for acute toxic liver injury, challenging established paradigms in hepatic redox biology.
-
RG7388: Potent Oral MDM2 Antagonist for p53 Pathway Activati
2026-08-06
RG7388 is a highly selective oral MDM2 antagonist that robustly activates the p53 pathway, leading to apoptosis in wild-type p53 cancer models. It demonstrates superior potency and tumor inhibition compared to first-generation compounds. The product is supplied by APExBIO and is widely used in translational oncology research.
-
Mitochondrial Antioxidant SkQ1 Uncouples Apoptosis from Musc
2026-08-05
This study demonstrates that the mitochondrial-targeted antioxidant SkQ1 can suppress mitochondrial-linked apoptotic activity, but does not prevent skeletal muscle atrophy or affect necroptosis markers in a mouse model of metastatic ovarian cancer. These findings challenge the assumed causal link between mitochondrial apoptosis and muscle wasting, with important implications for designing targeted interventions.
-
AAPH for In Vitro Oxidative Damage: Protocols and Innovation
2026-08-05
AAPH (2,2'-Azobis(2-methylpropionamidine) dihydrochloride) stands as the gold standard for controlled induction of oxidative stress in biomedical assays, particularly for modeling erythrocyte hemolysis and lipid peroxidation. Through well-documented workflows and troubleshooting strategies, researchers can leverage this reagent to probe antioxidant defenses and dissect redox-sensitive pathways with reproducibility and precision.
-
Laminin (925-933): Technical Guidance for Cell Adhesion Assa
2026-08-04
Laminin (925-933) is a defined Laminin B1 chain peptide for in vitro cell adhesion, migration, and chemotaxis assays, enabling precise dissection of receptor-mediated cell interactions with basement membrane components. It is not suitable for diagnostic or therapeutic uses and should not be applied outside rigorously controlled research protocols.
-
Neutrophil Extracellular Trap Formation in CML: Impact of TK
2026-08-04
This study identifies a significant increase in neutrophil extracellular traps (NETs) in chronic myeloid leukemia (CML) and reveals that tyrosine kinase inhibitors (TKIs) differentially modulate NET formation. These findings highlight a potential mechanistic link between TKI therapy, CML-associated thrombosis, and vascular toxicity, offering new directions for translational hematology research.
-
Bile Acid Retention Suppresses Antigen Presentation in MASH-
2026-08-03
This study uncovers a novel mechanism by which bile acid retention in MASH-related hepatocellular carcinoma (HCC) impairs antigen presentation and intrinsic tumor suppression. Targeting bile acid metabolism restores tumor immunogenicity and may enhance the efficacy of immunotherapy in metabolic liver cancer.